Home › Funds › Aristotle Capital Boston, LLC › CRL
Aristotle Capital Boston, LLC position in CRL
CHARLES RIV LABS INTL INC · Health Care
Aristotle Capital Boston, LLC reported holding 80,574 shares of CRL (CHARLES RIV LABS INTL INC) in its Q2 2026 13F filing — a position valued at US$18.3M, representing 1.23% of its reported portfolio and ranking #31 among its reported holdings. Aristotle Capital Boston, LLC has disclosed CRL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Aristotle Capital Boston, LLC's CRL position evolved
Aristotle Capital Boston, LLC first disclosed a stake in CRL in Q3 2023 at 158,904 shares (US$31.1M). The position peaked in Q1 2024 at 148,579 shares, worth US$40.3M. Across 12 filings, Aristotle Capital Boston, LLC increased the stake 2 time(s), trimmed it 9 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 80,574 shares valued at US$18.3M — a reduction of -16,860 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 158.90K | $31.14M | New |
| Q4 2023 | 153.67K | $36.33M | Reduce |
| Q1 2024 | 148.58K | $40.26M | Reduce |
| Q2 2024 | 150.69K | $31.13M | Add |
| Q3 2024 | 144.71K | $28.50M | Reduce |
| Q4 2024 | 130.16K | $24.03M | Reduce |
| Q1 2025 | 104.48K | $15.73M | Reduce |
| Q2 2025 | 96.35K | $14.62M | Reduce |
| Q3 2025 | 95.35K | $14.92M | Reduce |
| Q4 2025 | 86.21K | $17.20M | Reduce |
| Q1 2026 | 97.43K | $16.81M | Add |
| Q2 2026 | 80.57K | $18.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRL and 13F data
CRL (CHARLES RIV LABS INTL INC) is a Health Care company. 30 other funds we track also report a position in CRL — the largest reported positions include Allspring Global Investments Holdings, LLC (US$436.5M), ARIEL INVESTMENTS, LLC (US$341.6M), EARNEST PARTNERS LLC (US$254.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRL
- Allspring Global Investments Holdings, LLC 1.91M sh · $436.47M · Q2 2026
- ARIEL INVESTMENTS, LLC 1.51M sh · $341.59M · Q2 2026
- EARNEST PARTNERS LLC 1.12M sh · $254.01M · Q2 2026
- COOKE & BIELER LP 755.63K sh · $171.37M · Q2 2026
More on Aristotle Capital Boston, LLC
FAQ
How long has Aristotle Capital Boston, LLC held CRL?
Aristotle Capital Boston, LLC has disclosed CRL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Aristotle Capital Boston, LLC's current position in CRL?
As of Q2 2026, Aristotle Capital Boston, LLC holds 80.57K shares of CRL (CHARLES RIV LABS INTL INC), valued at $18.27M, representing 1.23% of its reported portfolio and ranking #31.
Has Aristotle Capital Boston, LLC been buying or selling CRL?
In the latest 13F filing (Q2 2026), Aristotle Capital Boston, LLC reduced its position in CRL. The position peaked in Q1 2024 at 148.58K shares.
Which other funds hold CRL?
Other major institutional holders of CRL include Allspring Global Investments Holdings, LLC, ARIEL INVESTMENTS, LLC, EARNEST PARTNERS LLC, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.